Viromed Medical AG Plans to Acquire All Shares of ActivCell Group AG by Way of a Capital Increase Against Contribution in Kind with Exclusion of Subscription Rights

News provided by

Sep. 18, 2024 15:15

공유
스크랩
인쇄
글자크기
Font Size
- ASmall
- AMedium
- ALarge
- AVery Large

PINNEBERG, GERMANY--(Business Wire / Korea Newswire)--Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus strategically expand its product portfolio. To this end, the Company has today signed a term sheet with the owners of ActivCell Group AG and will immediately enter into further negotiations with the objective of concluding an agreement. With the acquisition of ActivCell Group AG, Viromed expands the treatment spectrum of its products with additional indications and expects an accelerated market launch in the European Union with its own cold plasma product series.

ActivCell Group AG is active in the development and manufacture of cold plasma therapy pens and has received approval for its products (CE-Notified-Body-No. 0297) in category 2a in accordance with the EU directive 2017/745 on medical devices (Medical Device Regulation, MDR) for use in skin and wound treatment in human medicine.

The transaction is expected to be completed in the current 2024 financial year. The purchase price for the 100% takeover of ActivCell Group AG is expected to be in the mid-single-digit million-euro range. The purchase price is to be paid exclusively by granting new shares in the Company by making partial use of the Authorized Capital 2022 by means of a capital increase against contributions in kind, excluding shareholders’ subscription rights.

The closing of the transaction is subject to a final agreement with the shareholders of ActivCell Group AG.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240917445870/en/

Website: https://www.viromed-medical-ag.de/

Contact

Viromed Medical AG
Uwe Perbandt
CEO
kontakt@viromed-medical.de

This news is a press release provided by Viromed Medical AG. Korea Newswire follows these editorial guidelines.

Viromed Medical AG News Releases

바이로메드 메디컬, 액티브셀 그룹의 모든 주식을 신주인수권 배제 현물출자에 대한 유상증자 방식으로 인수할 계획

바이로메드 메디컬(Viromed Medical AG)(티커: VMED , ISIN: DE000A3MQR65, 이하 ‘바이로메드’, ‘회사’)이 스위스 액티브셀 그룹(ActivCell Group AG)의 모든 주식을 인수하여 제품 포트폴리오를 전략적으로 확장할 계획을 발표했다. 이를 위해 회사는 오늘 액티브셀 그룹의 소유주와 텀싯(term sheet)에 서명...

9월 18일 15:15

Viromed Medical AG Seeks Special Approval for Cold Plasma Device for the Prevention of Ventilator-Associated Pneumonia (VAP)

Viromed Medical AG (ISIN: DE000A3MQR65; “Viromed”) is launching a second pioneering study on the use of cold plasma for the prevention of ventilator-associated pneumonia (VAP). The study, under the scientific direction of Prof. Dr. Hortense Slevogt from the Hannover Medical School (MHH)...

7월 11일 15:50

... More

More News

All News Releases